stock-detail (FGEN)

Oncology Corporate Profile

Company Description

This company does not have any commercial products

This company does not have any pipeline products

Recent News Headlines

4/23/2017 12:18 pm

4/23/2017 12:18 pm

4/23/2017 12:18 pm

4/23/2017 12:18 pm

4/23/2017 12:18 pm

4/20/2017 12:18 pm

FibroGen Announces China FDA Approval of CTA to Conduct Pivotal Phase 2/3 Clinical Trial of Roxadustat in Anemia Associated With Lower Risk MDS

3/31/2017 11:00 am

[GlobeNewswire] - SAN FRANCISCO, March 31, 2017-- FibroGen, Inc., a science-based biopharmaceutical company, today announced the approval by the China Food and Drug Administration of the Company’ s clinical trial application ...

Positive Results Published in Nephrology Dialysis Transplantation From Two China Phase 2 Trials of Roxadustat for Treatment of Anemia in Chronic Kidney Disease

3/30/2017 11:00 am

[GlobeNewswire] - SAN FRANCISCO, March 30, 2017-- FibroGen, Inc., a science-based biopharmaceutical company, today announced that clinical results from two Phase 2 studies in China of roxadustat for the treatment of anemia ...

FIBROGEN INC Financials

3/7/2017 06:00 pm

FibroGen Reports Fiscal 2016 Financial Results

3/1/2017 09:00 pm

[GlobeNewswire] - SAN FRANCISCO, March 01, 2017-- FibroGen, Inc., a science-based biopharmaceutical company, today reported financial results for the year ended December 31, 2016, and provided an update on the company’ ...

FibroGen to Report Fiscal 2016 Financial Results on March 1, 2017

2/23/2017 03:03 am

[GlobeNewswire] - SAN FRANCISCO, Feb. 22, 2017-- FibroGen, Inc., a science-based biopharmaceutical company, today announced that it will report financial results for the year ended December 31, 2016, on Wednesday, March ...

FibroGen Announces Publication of Pamrevlumab (FG-3019) Clinical Data in Pancreatic Cancer Showing Safety and Improved Survival Outcomes in Combination with Chemotherapy

2/3/2017 04:00 pm

[GlobeNewswire] - SAN FRANCISCO, Feb. 03, 2017-- FibroGen, Inc.,, a science-based biopharmaceutical company, today announced that clinical results from the company’ s open-label, dose-escalation Phase 1/ 2 study of pamrevlumab ...